Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 6:51 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 13,619 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatologic Disorders Clear all
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

PDT vs Peels for Treatment of Actinic Keratoses

NCT04429308
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Photodynamic Therapy, Chemical Peels
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 2, 2026, 6:51 PM EST
Completed Phase 3 Interventional

Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

NCT00034125
View directory record Official record
Conditions
Breast Neoplasms
Interventions
LY353381, tamoxifen
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Miami, Florida • Shreveport, Louisiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Nov 2, 2026, 6:51 PM EST
Completed Phase 1Phase 2 Interventional

Activated PRP for Treatment of Androgenetic Alopecia

NCT05348343
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Autologous platelet-rich plasma
Biological
Lead sponsor
Santiste Medical Inc.
Industry
Eligibility
30 Years to 60 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Nov 2, 2026, 6:51 PM EST
Active, not recruiting Phase 3 Interventional

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

NCT05725018
View directory record Official record
Conditions
Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB
Interventions
EB-101 Surgical application of RDEB wounds
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
12 Months and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Redwood City, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Nov 2, 2026, 6:51 PM EST
Completed Phase 1 Interventional

Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer

NCT01846091
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive, Recurrent Head and Neck Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Nov 2, 2026, 6:51 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Tailored Intervention for Melanoma Patient's Families

NCT00816374
View directory record Official record
Conditions
Melanoma
Interventions
Reading materials and discussions, Questionnaires
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
21 Years and older
Enrollment
553 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
3
States / cities
Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Nov 2, 2026, 6:51 PM EST
Completed Phase 1 Interventional

A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases

NCT02780674
View directory record Official record
Conditions
Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc
Interventions
MEDI7734, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Anniston, Alabama • Birmingham, Alabama • Danbury, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Nov 2, 2026, 6:51 PM EST
Terminated Phase 1 Interventional

Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy

NCT01367990
View directory record Official record
Conditions
Alopecia, Radiodermatitis
Interventions
Norepinephrine
Drug
Lead sponsor
ProCertus BioPharm, Inc
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Nov 2, 2026, 6:51 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls

NCT05393076
View directory record Official record
Conditions
Pruritus
Interventions
Linerixibat
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Nov 2, 2026, 6:51 PM EST
Completed Not applicable Interventional

Genetic Testing for All Breast Cancer Patients (GET FACTS)

NCT04245176
View directory record Official record
Conditions
Breast Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Genetic Testing
Interventions
Standard Genetic Counseling, Quantitative Genetic Counseling
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 2, 2026, 6:51 PM EST
Completed Phase 3 Interventional Results available

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

NCT02953340
View directory record Official record
Conditions
Neutropenia, Breast Cancer
Interventions
SPI-2012, Pegfilgrastim, Docetaxel, Cyclophosphamide
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
49
States / cities
Tucson, Arizona • Yuma, Arizona • Hot Springs, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Nov 2, 2026, 6:51 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

NCT02346240
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Etanercept, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Nov 2, 2026, 6:51 PM EST
Completed Not applicable Interventional

Mindful Movement Program in Improving Quality of Life in Older Female Breast Cancer Survivors

NCT00903474
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Cancer Survivor, Cognitive/Functional Effects, Depression, Psychosocial Effects of Cancer and Its Treatment
Interventions
questionnaire administration, study of socioeconomic and demographic variables, CAM exercise therapy, psychosocial assessment and care, quality-of-life assessment, stress management therapy
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
50 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Nov 2, 2026, 6:51 PM EST
Completed No phase listed Observational

Biomarkers for Oral Cancer

NCT00341497
View directory record Official record
Conditions
Lichen Planus, Oral Leukoplakia, Mouth Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 110 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2025
U.S. locations
6
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Nov 2, 2026, 6:51 PM EST
Completed Not applicable Interventional Results available

Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema

NCT01326910
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Colloidal Oatmeal, Topical Cream
Drug · Device
Lead sponsor
Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.
Industry
Eligibility
6 Months to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
St. Petersburg, Florida • Miamiville, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2012 · Synced Nov 2, 2026, 6:51 PM EST
Completed Phase 3 Interventional Results available

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

NCT03529110
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab deruxtecan (T-DXd), Ado-trastuzumab emtansine (T-DM1)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
28
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 2, 2026, 6:51 PM EST
Recruiting Phase 3 Interventional

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

NCT07457918
View directory record Official record
Conditions
Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts
Interventions
Cantharidin
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Saint Augustine, Florida • Plainfield, Indiana • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 2, 2026, 6:51 PM EST
Completed Not applicable Interventional

Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

NCT00647218
View directory record Official record
Conditions
Breast Cancer
Interventions
Post-operative adjuvant therapy, neoadjuvant therapy, therapeutic surgical procedure, Radiation therapy with concurrent Paclitaxel, Hormonal Therapy
Drug · Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
6
States / cities
Frankling, Tennessee • Jackson, Tennessee • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Nov 2, 2026, 6:51 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers

NCT01694810
View directory record Official record
Conditions
Acne Vulgaris
Interventions
2% NVN1000 Topical Gel, 4% NVN1000 Topical Gel, 8% NVN1000 Topical Gel, Vehicle Topical Gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Nov 2, 2026, 6:51 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania

NCT04085510
View directory record Official record
Conditions
Breast Cancer Female, Breast Cancer, Breast Neoplasms, Neoplasms
Interventions
Contrast-enhanced mammogram
Device
Lead sponsor
Wendie Berg
Other
Eligibility
30 Years to 85 Years · Female only
Enrollment
1,647 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
3
States / cities
Cranberry Township, Pennsylvania • Monroeville, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Nov 2, 2026, 6:51 PM EST
Terminated Phase 1 Interventional

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

NCT03680560
View directory record Official record
Conditions
Solid Tumor, HER-2 Protein Overexpression
Interventions
ACTR T Cell Product, Trastuzumab
Biological · Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
New Haven, Connecticut • Miami, Florida • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Nov 2, 2026, 6:51 PM EST
Completed Not applicable Interventional

Reflexology: An Intervention for Advanced Breast Cancer

NCT01577420
View directory record Official record
Conditions
Breast Cancer
Interventions
Reflexology Sessions, Placebo Sessions
Other
Lead sponsor
Michigan State University
Other
Eligibility
21 Years and older · Female only
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
12
States / cities
Evanston, Illinois • Flint, Michigan • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2012 · Synced Nov 2, 2026, 6:51 PM EST
Recruiting No phase listed Observational

Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue

NCT06127797
View directory record Official record
Conditions
Breast Cancer
Interventions
Questionnaire/Interview
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 2, 2026, 6:51 PM EST
Completed Phase 1 Interventional

A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors

NCT05082610
View directory record Official record
Conditions
Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor
Interventions
HMBD-002, Pembrolizumab
Drug
Lead sponsor
Hummingbird Bioscience
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Nov 2, 2026, 6:51 PM EST